Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 6,501–6,600 of 15,747
Dulovic, A., Kessel, B., Harries, M., Becker, M., Ortmann, J., Griesbaum, J., Juengling, J., Junker, D., Hernández, P., Gornyk, D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828053 · Cited by 12
“While heterologous and vector vaccination dosing intervals in our mix and match cohort adhere more closely to those extended intervals (1), time periods for mRNA vaccine dosing across our study population mimic 21 or 28 days from clinical trials (3, 4) and licensing agreements (50, 51) making them unlikely contributor…”
BackgroundRegulating Immune Responses Induced by PEGylated Messenger RNA–Lipid Nanoparticle Vaccine
Jo, H., Jeoung, J., Kim, W., & Jeoung, D. (2024) · Vaccines · doi:10.3390/vaccines13010014 · Cited by 22
Makiguchi, T., Fukushima, T., Tanaka, H., Taima, K., Takayasu, S., & Tasaka, S. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14352 · Cited by 11
“The clinical trial demonstrated that efficacy in preventing COVID-19 was 95%, and the incidence of severe adverse events was low.(2) However, cancer patients accounted for only 4% of the participants.”
BackgroundCritical assessment of the impact of vaccine-type and immunity on the burden of COVID-19
Taboe, H. B., Asare-Baah, M., Iboi, E., & Ngonghala, C. N. (2023) · Mathematical Biosciences · doi:10.1016/j.mbs.2023.108981 · Cited by 14
Levi, Y., Brandeau, M. L., Shmueli, E., & Yamin, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-56561-w · Cited by 16
Aboud, F. M., Hussein, R. S., & Hassan, R. M. (2022) · The Egyptian Rheumatologist · doi:10.1016/j.ejr.2022.12.003 · Cited by 11
“[26] compared vaccine versus placebo injection and revealed 95 % protection against Covid-19 in vaccinated persons >16 years of age.”
Xu, J., Zhang, Y., Qu, P., Shamseldin, M. M., Yoo, S. J., Misny, J., Thongpan, I., Mahesh, K. C., Hall, J. M., Evans, J. P., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2220403120 · Cited by 15
Kisakov, D. N., Kisakova, L. A., Borgoyakova, M. B., Starostina, E. V., Taranov, O. S., Ivleva, E. K., Pyankov, O. V., Zaykovskaya, A. V., Щербаков, Д. Н., Рудометов, А. П., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112259 · Cited by 13
“The spread of SARS-CoV-2 has stimulated research into the development of new vaccines, including those based on mRNA and DNA [2,3].”
BackgroundReitemeier, J., Metro, J., & Bohn, P. W. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116457 · Cited by 12
Morisaki, S., Onishi, H., Morisaki, T., Kubo, M., Umebayashi, M., Tanaka, H., Koya, N., Nakagawa, S., Tsujimura, K., Yoshimura, S., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1565696 · Cited by 15
Yuzefpolskiy, Y., Morawski, P. A., Fahning, M. L., Speake, C., Lord, S. M., Chaudhary, A., Morishima, C., Wener, M. H., Kita, M., McCarthy, L. H., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2101142 · Cited by 13
COVID-19 and Pro-environmental Behaviour at Destinations Amongst International Travellers
Calder, G., Radić, A., Ryu, H. B., Ariza‐Montes, A., & Han, H. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.879300 · Cited by 14
Antibody response to COVID-19 vaccine: A point of view that can help to optimize dose distribution
Pieri, M., Nicolai, E., Ciotti, M., Nuccetelli, M., Sarubbi, S., Pelagalli, M., & Bernardini, S. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108406 · Cited by 13
Yoshifuji, A., Toda, M., Ryuzaki, M., Kikuchi, K., Kawai, T., Sakai, K., Oyama, E., Koinuma, M., Katayama, K., Uehara, Y., et al. (2022) · Renal Replacement Therapy · doi:10.1186/s41100-022-00427-2 · Cited by 11
“In addition, known adverse reactions to vaccines include pain at the vaccination site, itching, general malaise, headache, chills, myalgia, arthralgia, and fever, although these symptoms generally improve within 2 days [1, 4].”
BackgroundYoda, T., Suksatit, B., Tokuda, M., & Katsuyama, H. (2022) · Vaccines · doi:10.3390/vaccines10071041 · Cited by 14
“In particular, three vaccines had ≥90% efficacy rates: the BNT162b2 vaccine (95% protection against COVID-19) [4], the ChAdOx1 nCoV-19 vaccine (90% protection against COVID19) [5], and the mRNA-1273 vaccine (94.”
BackgroundConsiderations on the Design of Lipid-based mRNA Vaccines Against Cancer
Meulewaeter, S., Zhang, Y., Wadhwa, A., Fox, K., Lentacker, I., Harder, K. W., Cullis, P. R., Smedt, S. C. D., Cheng, M. H. Y., & Verbeke, R. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168385 · Cited by 13
Marasco, V., Piciocchi, A., Candoni, A., Pagano, L., Guidetti, A., Musto, P., Bruna, R., Bocchia, M., Visentin, A., Turrini, M., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18385 · Cited by 13
“3 In healthy subjects, mRNA vaccines were demonstrated to be effective in reducing COVID19, in particular severe forms.(4,5) However, humoral and cellular response after twodose vaccination is reduced in HM patients when compared to the general population.”
BackgroundGarcia-Grimshaw, M. A., Ceballos‐Liceaga, S. E., Michel‐Chávez, A., García-Alanis, M., Cadena‐Fernández, A., Galnares‐Olalde, J. A., Carbajal‐Sandoval, G., Carrillo-García, D. A., Hernández-Valdivia, N., Hernández‐Vanegas, L. E., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.058 · Cited by 11
Covid-19: How independent were the US and British vaccine advisory committees?
Thacker, P. D. (2021) · BMJ · doi:10.1136/bmj.n1283 · Cited by 12
Newman, P. A., Reid, L., Tepjan, S., Fantus, S., Allan, K., Nyoni, T., Guţă, A., & Williams, C. C. (2022) · medRxiv · doi:10.1101/2022.03.15.22272438 · Cited by 12
Allogeneic hematopoietic stem cell transplantation in the COVID-19 era
Bordat, J., Maury, S., & Leclerc, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1100468 · Cited by 15
“BNT162b2, in which the mRNA encodes the RBD of S protein, was the first to show a clinical efficacy against SARS-CoV-2 infection in a phase 3 study (62) with a protection rate of 95%.”
BackgroundOtolaryngologic Side Effects After COVID ‐19 Vaccination
Ahsanuddin, S., Jin, R., Dhanda, A. K., Georges, K., Baredes, S., Eloy, J. A., & Fang, C. H. (2023) · The Laryngoscope · doi:10.1002/lary.30923 · Cited by 16
Long-term adaptive response in COVID-19 vaccine recipients and the effect of a booster dose
Perico, L., Todeschini, M., Casiraghi, F., Mister, M., Pezzotta, A., Peracchi, T., Tomasoni, S., Trionfini, P., Benigni, A., & Remuzzi, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1123158 · Cited by 15
“Two mRNA vaccines that exhibited strong immunogenicity and efficacy were approved (2, 3) between December 2020 and February 2021.”
BackgroundCOVID-19 vaccine failure in a patient on rituximab therapy
Chilimuri, S. S., Mantri, N., Zahid, M., & Sun, H. (2021) · Rheumatology Advances in Practice · doi:10.1093/rap/rkab038 · Cited by 12
He, Y., Pilkington, E. H., Kang, H. J., Fong, W., Clulow, A. J., Johnston, A. P. R., & Pouton, C. W. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101578 · Cited by 17
Saunders, K. O., Lee, E., Parks, R., Martinez, D. R., Li, D., Chen, H., Edwards, R. J., Gobeil, S., Barr, M., Mansouri, K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.17.431492 · Cited by 14
Immunology of RNA-based vaccines: The critical interplay between inflammation and expression
Tregoning, J. S., Wang, Z., Sridhar, S., Shattock, R. J., & DeRosa, F. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.011 · Cited by 25
Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults
Oyebanji, O. A., Mylonakis, E. E., & Canaday, D. H. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.11.002 · Cited by 15
“110 Although this carries the risk of extending the period of partial vaccination, a single dose of the BNT162b2 vaccine produces favorable immunogenicity and clinical efficacy 29,110–112 and is durable.”
Quelling Public Fears About Guillain-Barré Syndrome and COVID-19 Vaccination
BOURDETTE, D. N., & Killestein, J. (2021) · Neurology · doi:10.1212/wnl.0000000000011882 · Cited by 13
Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case–Control Study
Hara, M., Furue, T., Fukuoka, M., Iwanaga, K., Matsuishi, E., Miike, T., SAKAMOTO, Y., Mukai, N., Kinugasa, Y., Shigyo, M., et al. (2022) · Vaccines · doi:10.3390/vaccines10050779 · Cited by 11
“, New York, NY, USA; BioNTech Manufacturing GmbH, Mainz, Germany; Comirnaty) [1] and 94.”
BackgroundInfluentialAnalysis of People’s Attitude Toward COVID-19 Vaccine and Its Information Sources in Thailand
Yoda, T., Suksatit, B., Tokuda, M., & Katsuyama, H. (2022) · Cureus · doi:10.7759/cureus.22215 · Cited by 14
“In particular, various studies on vaccine efficacy have demonstrated extremely high efficacy rates [3,22-24], and the increased credibility of these studies may have contributed to the higher willingness to vaccinate.”
BackgroundDong, Y., He, Z., Liu, T., Huang, J. V., Zhang, C. J. P., Akinwunmi, B. O., & Ming, W. (2022) · Vaccines · doi:10.3390/vaccines10060832 · Cited by 13
Qiao, N., Hori, M., Naito, M., Chang, H., Ogura, S., Suzuki, M., Kimura, T., Fukushima, S., Kim, H. J., Uchida, S., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123515 · Cited by 15
Elamin, M. Y., Maslamani, Y. A., Muaddi, M. A., Alameer, A. A., Alqassim, A. Y., Doweri, A. A., Zaylaee, M. M., Rayani, H. Y., Darraj, A., Hejri, Y. M., et al. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.06.014 · Cited by 12
A case of acute interstitial nephritis following the Pfizer–BioNTech COVID-19 vaccine
de la Flor, J. C., Grávalos, T. L., Alonso, M., Cebollada, P. S., Sierra, C. A., Cícero, E. R., Bayas, G. G., & del Pozoa, M. R. (2022) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2021.05.007 · Cited by 14
“6–3,4 x103/uL (14-48%) Eosinófilos 0,44 (5) 0,72(8,9) 0,13(1,1) 0,21(2,7) 0-0,6 x103/uL (0-7%) LDH 215 318 289 242 135 - 214 IU/L Bilirrubina total 0,5 0,3 0,5 0,3 0,1 – 1 mg/dL Proteínas totales 5,4 6,4 6,5 5,6 6,4 – 8,7 g/dL Albúmina sérica 3,9 4,2 4 3,39 3 – 5,5 g/dL GOT 22 25 27 9 5- 32 IU/L GPT 23 23 22 17 5 – 33…”
Clinical Outcomes of Adult Patients Hospitalized with COVID-19 after Vaccination
Kalligeros, M., Shehadeh, F., Mylona, E. K., Kaczynski, M., Kalagara, S., Atalla, E., Tsikala-Vafea, M., & Mylonakis, E. E. (2021) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed6040175 · Cited by 13
Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges
Hakim, A., Hasan, M. M., Hasan, M., Lokman, S. M., Azim, K. F., Raihan, T., Chowdhury, P. A., & Azad, A. K. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.637554 · Cited by 15
Valera-Rubio, M., Sierra-Torres, M. I., García, R. C., Ramos, J., López-Márquez, M. R., Cruz-Salgado, Ó., & Calleja‐Hernández, M. Á. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2022478 · Cited by 13
“The safety aspects collected in the survey were graded according to the US Food and Drugs Administration (FDA) guidelines ‘Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials’ [19,20] although some variables not included in the guidelines were also added (s…”
MethodResultMontoya, J. C., Collett, S., Fernandez‐Ruiz, D., Earnest, L., Edeling, M. A., Yap, A. H. Y., Wong, C. Y., Cooney, J. P., Davidson, K. C., Roberts, J., et al. (2024) · Organoids · doi:10.3390/organoids3010002 · Cited by 13
“Early clinical trials demonstrated an efficacy of approximately 95% in preventing symptomatic COVID-19 disease [1].”
BackgroundReducing COVID-19 Cases and Deaths by Applying Blockchain in Vaccination Rollout Management
Medina, J. H., Cessa-Rojas, R., & Umpaichitra, V. (2021) · IEEE Open Journal of Engineering in Medicine and Biology · doi:10.1109/ojemb.2021.3093774 · Cited by 12
“5 [32]; a case fatality rate of 2/100 [33]; an average infection, incubation, and critical infection periods of 9, 5, and 19 days, respectively [34]–[37]; a probability of infection awareness of 2/100 [38]; a vaccine efficacy of 95% [39], [40]; the start of the vaccination rollout on day 1; a daily vaccination rate of…”
mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases
Brandi, R., Paganelli, A., D’Amelio, R., Giuliani, P., Lista, F. R., Salemi, S., & Paganelli, R. (2024) · Vaccines · doi:10.3390/vaccines12121418 · Cited by 13
Comparing SARS-CoV-2 Antibody Responses after Various COVID-19 Vaccinations in Healthcare Workers
Kim, Y., Minn, D., Chang, S. H., & Suh, J. S. (2022) · Vaccines · doi:10.3390/vaccines10020193 · Cited by 12
“mRNA vaccines, such as BNT162b2 and mRNA-1273, reportedly have an efficacy of 95% [2,3] and are used in several countries at present.”
BackgroundMauro, F. R., Giannarelli, D., Galluzzo, C. M., Visentin, A., Frustaci, A. M., Sportoletti, P., Vitale, C., Reda, G., Gentile, M., Levato, L., et al. (2023) · Cancers · doi:10.3390/cancers15112993 · Cited by 11
“During the first pandemic, two doses of the BNT162b2 vaccine conferred protection against COVID-19 in 94–95% of healthy subjects [23,24].”
BackgroundMyers, M. A., Dunikoski, L., Brantner, R., Fletcher, D., Saltzberg, E. E., Urdaneta, A. E., Wedro, B. C., & Giwa, A. (2022) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2022.11.005 · Cited by 15
Health and Public Health Implications of COVID ‐19 in Asian Countries
Miyawaki, A., & Tsugawa, Y. (2021) · Asian Economic Policy Review · doi:10.1111/aepr.12358 · Cited by 17
Management of Acute Coronary Syndrome in the COVID Era
Bahuva, R., Aoun, J., & Goel, S. S. (2021) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1049 · Cited by 17
Coria, L. M., Rodriguez, J. M., Demaría, A., Bruno, L. A., Medrano, M. R., Castro, C. P., Castro, E. F., Priore, S. A. D., Hernando-Insúa, A., Kaufmann, I. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45180-8 · Cited by 11
Tauzin, A., Gong, S., Beaudoin-Bussières, G., et al. (2021) · medRxiv · doi:10.1101/2021.09.17.21263532 · Cited by 3
Allan, J., McMillan, D., & Levi, M. L. (2021) · Cureus · doi:10.7759/cureus.20810 · Cited by 12
“Local and systemic reactogenicity are known and expected occurrences after the Pfizer and Moderna mRNA COVID-19 vaccinations and are seen in a considerable percentage of those surveyed.”
BackgroundInfluentialPhotodynamic Therapy: A Rational Approach Toward COVID-19 Management
Tariq, R., Khalid, U. A., Kanwal, S., Adnan, F., & Qasim, M. (2021) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2020.00036 · Cited by 14
Li, D., Debbas, P., Cheng, S. C., et al. (2021) · medRxiv · doi:10.1101/2021.12.05.21266089 · Cited by 12
Meyers, E., Rop, L. D., Deschepper, E., Duysburgh, E., Burghgraeve, T. D., Ngoc, P. V., Digregorio, M., Delogne, S., Coen, A., Clercq, N. D., et al. (2022) · European Journal of General Practice · doi:10.1080/13814788.2022.2149732 · Cited by 12
“On top of that, age groups that typically populate NHs in Belgium were vastly underrepresented in the vaccine efficacy trial [5,6].”
BackgroundThe current therapeutic cancer vaccines landscape in non‐small cell lung cancer
Chen, S., Cheng, S., Cai, J., Liu, Z., Li, H., Wang, P., Li, Y., Yang, F., Chen, K., & Qiu, M. (2024) · International Journal of Cancer · doi:10.1002/ijc.35088 · Cited by 20
“114,115 In vaccination, antigen-encoding mRNA is released from carriers like lipid nanoparticles (LNP) into cytoplasm where translated it into antigens. mRNA vaccines offer advantages over DNA vaccines, avoiding genomic integration.”
Maximizing Completion of the Two-Dose COVID-19 Vaccine Series with Aid from Infographics
Crutcher, M. M., & Seidler, P. M. (2021) · Vaccines · doi:10.3390/vaccines9111229 · Cited by 13
SARS-CoV-2 vaccine effectiveness in immunosuppressed kidney transplant recipients
Chemaitelly, H., AlMukdad, S., Joy, J. P., Ayoub, H. H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Tang, P., Hasan, M. R., Coyle, P., et al. (2021) · doi:10.1101/2021.08.07.21261578 · Cited by 12
Durability of humoral and cell‐mediated immune response after SARS‐CoV‐2 mRNA vaccine administration
Mihaylova, A., Lesichkova, S., Baleva, M. P., Nikolova-Vlahova, M. K., Kundurzhiev, T., Kolevski, A., & Naumova, E. J. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28360 · Cited by 12
Molecular Targeting of the Most Functionally Complex Gene in Precision Oncology: p53
Brown, D. W., Beatty, P. H., & Lewis, J. D. (2022) · Cancers · doi:10.3390/cancers14215176 · Cited by 13
Kunyk, D., Plotnikova, M. A., Bespalov, M., Shevyrev, D., Klotchenko, S. A., Ivanov, R. A., & Reshetnikov, V. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188986 · Cited by 17
“…served as a starting point for the development of the first mRNA vaccines, RNA-1273 (Moderna, Cambridge, MA, USA) and BNT162b2 (Pfizer (New York, NY, USA)/BioNTech (Mainz, Germany)), which successfully passed clinical trials during the COVID-19 pandemic and were approved in 2020 and 2021 [5,6].”
Long, S., Olsen, R., Christensen, P., et al. (2021) · medRxiv · doi:10.1101/2021.02.26.21252227 · Cited by 2
Atagündüz, P., Keser, G., & Soy, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.734279 · Cited by 17
Grosso, F. M., Castrofino, A., Castillo, G. D., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.02.003 · Cited by 12
Keeshan, A., Galipeau, Y., Heiskanen, A., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-077714 · Cited by 12
Bell's palsy after Sputnik V COVID‐19 (Gam‐COVID‐Vac) vaccination
Mirmosayyeb, O., Barzegar, M., Rezaei, M., Baharlouie, N., & Shaygannejad, V. (2022) · Clinical Case Reports · doi:10.1002/ccr3.5468 · Cited by 13
Yılmaz, F. K., Çakır, M., İkiışık, H., & Maral, İ. (2023) · Vaccines · doi:10.3390/vaccines11050943 · Cited by 12
“According to the interim analysis results for Sinovac (CoronaVac) and the completed phase 3 study results of the mRNA vaccine Pfizer-BioNTech, fewer COVID-19 cases were detected in the vaccine group compared to the placebo group [30,31].”
ResultObesity and COVID-19 Pandemics: Epidemiology, Mechanisms, and Management
Yang, Y., Song, Y., & Hou, D. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s441762 · Cited by 16
Farias, J. P., da Silva, P. D. S., Fogaça, M. M. C., Santana, I. V. R., Luiz, W. B., Birbrair, A., & Amorim, J. H. (2022) · Journal of Virology · doi:10.1128/jvi.00177-22 · Cited by 14
“In November 2021, the Brazilian Ministry of Health recommended a booster dose with the Pfizer (BNT126b2) COVID-19 vaccine (RNA-based vaccine) (14, 15) for people over 18 years old at least 5 months after the second dose (9).”
Backgroundvan Doremalen, N., Schulz, J. E., Adney, D. R., Saturday, T. A., Fischer, R., Yinda, C., Thakur, N., Newman, J., Ulaszewska, M., Belij-Rammerstorfer, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1343927/v1 · Cited by 14
Anti-Idiotypic mRNA Vaccine to Treat Autoimmune Disorders
Niazi, S. K. (2023) · Vaccines · doi:10.3390/vaccines12010009 · Cited by 18
“Lastly, mRNA vaccines, including the Pfizer-BioNTech and Moderna COVID-19 vaccines, instruct cells to produce pathogen proteins via messenger RNA [6], showcasing the diverse strategies employed in modern vaccine development.”
BackgroundNucleic Acid Vaccine Platform for DENGUE and ZIKA Flaviviruses
Mourosi, J. T., Awe, A., Jain, S., & Batra, H. (2022) · Vaccines · doi:10.3390/vaccines10060834 · Cited by 16
Chow, R. M., Rajput, K., Howie, B. A., & Varhabhatla, N. (2021) · Pain Practice · doi:10.1111/papr.13062 · Cited by 12
Editorial: Nanomedicine development and clinical translation
Peng, C. (2024) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1458690 · Cited by 15
Nistor, G. I., Dillman, R. O., Robles, R. M., Langford, J. L., Poole, A. J., Sofro, M. A. U., Nency, Y. M., Jonny, J., Yana, M. L., Karyana, M., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2100189 · Cited by 13
Plasma protein corona on silica nanoparticles enhances exocytosis
Dietz, L., Simon, J., Speth, K. R., Landfester, K., & Mailänder, V. (2025) · Biomaterials Science · doi:10.1039/d4bm01189a · Cited by 14
Giannoccaro, M. P., Vacchiano, V., Leone, M., Camilli, F., Zenesini, C., Panzera, I., Balboni, A., Tappatà, M., Borghi, A., Salvi, F., et al. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11142-7 · Cited by 13
“It is likely that the higher mRNA content (100 μg in the mRNA-1273 vs 30 μg in the BNT162b2 vaccine), together with the longer interval between the two doses for mRNA-1273 (4 weeks vs 3 weeks for the BNT162b2 vaccine) could account for the higher seroconversion rate and RBD antibody levels as well as for the higher re…”
BackgroundResultInfluentialComparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19
Wei, J., Zhang, W., Doherty, M., Wallace, Z. S., Sparks, J. A., Lu, N., Li, X., Zeng, C., Lei, G., & Zhang, Y. (2023) · BMC Medicine · doi:10.1186/s12916-023-02795-w · Cited by 15
“Results from the phase III clinical trials showed 95% efficacy for BNT162b2 [10] and 70% efficacy for ChAdOx1 [11] against COVID-19 after two vaccine doses.”
MethodPodrazil, M., Táborská, P., Stakheev, D., Rataj, M., Lašťovička, J., Vlachova, A., Pohunek, P., Bartůňková, J., & Smrž, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.892277 · Cited by 13
Byrne, J., Gu, L., Leon, A. A. G., Gaillard, C. M., Saini, G., Alalwan, D., Tomás‐Cortázar, J., Kenny, G., Donohue, S., Reynolds, B., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1445653 · Cited by 13
NOTTO COVID-19 vaccine guidelines for transplant recipients
Ramesh, V., Kute, V. B., Agarwal, S., Prakash, J., Guleria, S., Shroff, S., Sharma, A., Varma, P. P., Prasad, N., Sahay, M., et al. (2021) · Indian Journal of Nephrology · doi:10.4103/ijn.ijn_64_21 · Cited by 12
An update on SARS-CoV-2 immunization and future directions
Rana, R., Kant, R., Kumra, T., Gupta, S. V., Rana, D. S., & Ganguly, N. K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1125305 · Cited by 14
An S1-Nanoparticle Vaccine Protects against SARS-CoV-2 Challenge in K18-hACE2 Mice
van Oosten, L., Yan, K., Rawle, D. J., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00844-22 · Cited by 12
The role of noncoding RNAs in cancer lipid metabolism
Wang, Y., Li, Q., Wang, S., Wang, B., Jin, Y., Hu, H., Fu, Q., Wang, J., Wu, Q., Qian, L., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1026257 · Cited by 13
“Scientists have developed relevant vaccines, such as the BNT162b2 mRNA COVID-19 vaccine (84) and the mRNA-1273 vaccine (85, 86), which have achieved good immune effects in clinical applications.”
BackgroundVisalli, G., Laganà, A., Giudice, D. L., Calimeri, S., Caccamo, D., Trainito, A., Pietro, A. D., & Facciolà, A. (2023) · Vaccines · doi:10.3390/vaccines11020217 · Cited by 13
Papadopoli, R., Sarro, C. D., Palleria, C., Gallelli, L., Pileggi, C., & Sarro, G. D. (2021) · Vaccines · doi:10.3390/vaccines9121494 · Cited by 12
“Finally, although our study does not provide data on the effect of different ethnic groups, recent US [34] and UK [23] studies highlighted a greater seropositivity in non-white groups after BNT162b2 mRNA vaccination.”
ResultRousculp, M. D., Hollis, K. A., ZIEMIECKI, R. M., Odom, D. M., Marchese, A. M., Montazeri, M., Odak, S., Jackson, L., Miller, A., & Toback, S. L. (2024) · Vaccines · doi:10.3390/vaccines12010083 · Cited by 10
“Reactogenicity may increase after subsequent COVID-19 vaccine doses compared to the fi rst Reactogenicity may increase after subsequent COVID-19 vaccine doses compared to the first dose [14,15,17]. dose [14,15,17].”
BackgroundEgilmezer, E., & Rawlinson, W. D. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2227 · Cited by 11
Tucker, M., Azar, M. M., Cohen, E., Gan, G., Deng, Y., Palacios, C. F., & Malinis, M. F. (2022) · Transplant Infectious Disease · doi:10.1111/tid.13876 · Cited by 13
COVID-19 vaccination and liver disease
Ozaka, S., Kobayashi, T., Mizukami, K., & Murakami, K. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i48.6791 · Cited by 14
T and B cell responses in different immunization scenarios for COVID-19: a narrative review
Mortari, E. P., Ferrucci, F., Zografaki, I., Carsetti, R., & Pacelli, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1535014 · Cited by 18
Long-Term, CD4+ Memory T Cell Response to SARS-CoV-2
Wirsching, S., Harder, L. H., Heymanns, M., Gröndahl, B., Hilbert, K., Kowalzik, F., Meyer, C. U., & Gehring, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.800070 · Cited by 16
(2022) · doi:10.1101/2022.04.16.22273937 · Cited by 12
“4 Pain, erythema, swelling, fever, headache, and myalgia were the most common systemic or local reactions reported [11].”
BackgroundModel‐Informed Drug Development Applications and Opportunities in mRNA ‐ LNP Therapeutics
Zhou, J., Rao, R. P., Shapiro, M. E., Tania, N., Herron, J. C., Musante, C. J., & Hughes, J. H. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3641 · Cited by 16
COVID Vaccination in Cancer Patients: What Vaccination Priority Strategies Should There Be?
Silvestris, N., Brunetti, O., Bernardini, R., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.641388 · Cited by 12
Wang, J., Young, B. E., Li, D., Seppo, A., Zhou, Q., Wiltse, A., Nowak-Wegrzyn, A. H., Murphy, K., Widrick, K., Diaz, N., et al. (2022) · Vaccines · doi:10.3390/vaccines10060980 · Cited by 14
“Currently, COVID-19 mRNA vaccination is the most effective way to prevent SARS-CoV-2 infection and transmission [21].”
BackgroundIs the mRNA COVID-19 Vaccine Safe in Patients With a Prior History of Myocarditis?
Shahid, R., Tang, W. H. W., Klein, A. L., Kwon, D. H., & Amdani, S. M. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.06.011 · Cited by 12
“The messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines BNT162b2 and mRNA1273 have both demonstrated efficacy in decreasing COVID-19 hospitalizations and deaths.(1,2) There have been numerous reports linking these vaccines to”
BackgroundWong‐Chew, R. M., Ramírez, J. B. D., Carbajal, P. B., León, M. L. G., Angel-Ambrocio, A. H., Velázquez, X. V., Maldonado, L. A. C., González, Y. V., Martínez, L. M. V., Bautista, D. G., et al. (2021) · Acta Médica Grupo Ángeles · doi:10.35366/101742 · Cited by 26
Longitudinal monitoring of mRNA-vaccine-induced immunity against SARS-CoV-2
Monzon‐Posadas, W. O., Zorn, J., Peters, K., Baum, M., Proksch, H., Schlüter, C. B., Menting, T., Pušnik, J., & Streeck, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1066123 · Cited by 13
“The BNT162b2 and mRNA-1273 vaccines demonstrated an outstanding efficacy of over 90% reduction in severe COVID-19 cases and proved safe for use (1, 2).”
Background
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.